$NNVC
NANOVIRICIDES, INC. Stock $nnvc

$nnvc Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-K Financial Statement

#000114420417050412 Filed on September 28, 2017

Income Statement

Concept	2017 Q2	2017	2016 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$990.0K	$4.069M	$890.0K
YoY Change	11.24%	6.23%	-15.24%
% of Gross Profit
Research & Development	$1.260M	$5.532M	$1.600M
YoY Change	-21.25%	10.0%	15.11%
% of Gross Profit
Depreciation & Amortization	$160.0K	$654.7K	$160.0K
YoY Change	0.0%	0.52%	14.29%
% of Gross Profit
Operating Expenses	$2.250M	$9.601M	$2.500M
YoY Change	-10.0%	8.37%	2.46%
Operating Profit		-$9.601M
YoY Change		8.37%
Interest Expense	-$90.00K	$780.8K	$1.230M
YoY Change	-107.32%	-25.1%	-32.79%
% of Operating Profit
Other Income/Expense, Net	-$220.0K	-$703.8K	-$380.0K
YoY Change	-42.11%	-62.27%	22.58%
Pretax Income	-$2.560M	-$10.30M	-$1.650M
YoY Change	55.15%	-3.92%	79.35%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.560M	-$10.30M	-$1.650M
YoY Change	55.15%	-3.92%	79.35%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.17
Diluted Earnings Per Share	-$812.7K	-$0.17	-$569.0K
COMMON SHARES
Basic Shares Outstanding	63.07M shares	60.10M shares
Diluted Shares Outstanding		60.10M shares

Balance Sheet

Concept	2017 Q2	2017	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.10M	$15.10M	$24.16M
YoY Change	-37.5%	-37.51%	-23.23%
Cash & Equivalents	$15.10M	$15.10M	$24.16M
Short-Term Investments
Other Short-Term Assets	$190.0K	$190.2K	$220.0K
YoY Change	-13.64%	-13.35%
Inventory
Prepaid Expenses	$190.2K		$219.5K
Receivables
Other Receivables
Total Short-Term Assets	$15.29M	$15.29M	$24.38M
YoY Change	-37.29%	-37.29%	-23.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.27M	$11.27M	$11.76M
YoY Change	-4.16%	-4.16%	-1.69%
Goodwill
YoY Change
Intangibles	$383.2K		$391.5K
YoY Change	-2.11%		-2.07%
Long-Term Investments
YoY Change
Other Assets	$60.00K	$58.93K	$100.0K
YoY Change	-40.0%	-40.8%	-28.57%
Total Long-Term Assets	$11.71M	$11.71M	$12.25M
YoY Change	-4.4%	-4.4%	-2.02%
TOTAL ASSETS
Total Short-Term Assets	$15.29M	$15.29M	$24.38M
Total Long-Term Assets	$11.71M	$11.71M	$12.25M
Total Assets	$27.00M	$27.00M	$36.63M
YoY Change	-26.29%	-26.29%	-17.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$480.0K	$476.5K	$860.0K
YoY Change	-44.19%	-44.85%	109.76%
Accrued Expenses	$34.00K	$34.00K	$35.60K
YoY Change	-4.49%	-4.49%	24.85%
Deferred Revenue
YoY Change
Short-Term Debt	$3.960M	$3.956M	$5.470M
YoY Change	-27.61%	-27.74%
Long-Term Debt Due			$5.475M
YoY Change
Total Short-Term Liabilities	$4.666M	$4.666M	$6.744M
YoY Change	-30.82%	-30.82%	1022.33%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$3.130M
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$2.020M	$2.015M	$3.710M
YoY Change	-45.55%	-45.64%	-19.7%
Total Long-Term Liabilities	$2.015M	$2.015M	$6.841M
YoY Change	-70.54%	-70.54%	-42.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.666M	$4.666M	$6.744M
Total Long-Term Liabilities	$2.015M	$2.015M	$6.841M
Total Liabilities	$6.681M	$6.681M	$13.59M
YoY Change	-50.82%	-50.82%	9.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$75.13M		-$64.82M
YoY Change	15.9%		19.82%
Common Stock	$63.31K		$58.18K
YoY Change	8.81%		1.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.32M	$20.32M	$23.05M
YoY Change
Total Liabilities & Shareholders Equity	$27.00M	$27.00M	$36.63M
YoY Change	-26.29%	-26.29%	-17.09%

Cashflow Statement

Concept	2017 Q2	2017	2016 Q2
OPERATING ACTIVITIES
Net Income	-$2.560M	-$10.30M	-$1.650M
YoY Change	55.15%	-3.92%	79.35%
Depreciation, Depletion And Amortization	$160.0K	$654.7K	$160.0K
YoY Change	0.0%	0.52%	14.29%
Cash From Operating Activities	-$1.010M	-$7.898M	-$1.380M
YoY Change	-26.81%	15.65%	10.4%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	$165.0K	-$60.00K
YoY Change	-33.33%	-65.37%	-95.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$40.00K	-$165.0K	-$60.00K
YoY Change	-33.33%	-65.37%	-95.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-1.000M	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-1.010M	-$7.898M	-1.380M
Cash From Investing Activities	-40.00K	-165.0K	-60.00K
Cash From Financing Activities	0.000	-1.000M	0.000
Net Change In Cash	-1.050M	-$7.898M	-1.440M
YoY Change	-27.08%	15.65%	-41.22%
FREE CASH FLOW
Cash From Operating Activities	-$1.010M	-$7.898M	-$1.380M
Capital Expenditures	-$40.00K	$165.0K	-$60.00K
Free Cash Flow	-$970.0K	-$8.063M	-$1.320M
YoY Change	-26.52%	10.36%	2540.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017	nnvc	Software Disposal Noncash Adjustment SoftwareDisposalNoncashAdjustment	0	USD
CY2016	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	345589	USD
CY2017	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	328458	USD
CY2016	us-gaap	Depreciation Depreciation	651275	USD
CY2017	us-gaap	Depreciation Depreciation	654685	USD
CY2016	us-gaap	Adjustment For Amortization AdjustmentForAmortization	8270	USD
CY2017	us-gaap	Adjustment For Amortization AdjustmentForAmortization	8269	USD
CY2016	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	541922	USD
CY2016	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5033	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6829195	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7897746	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7305563	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9062724	USD
CY2016	us-gaap	Interest Paid InterestPaid	1036115	USD
CY2017	us-gaap	Interest Paid InterestPaid	173589	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24162185	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31467748	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15099461	USD
CY2017	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1347748	USD
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1427218	USD
CY2017	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-607178	USD
CY2016	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-660000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-10304490	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-10724629	USD
CY2017	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	1696318	USD
CY2017	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-29292	USD
CY2017	us-gaap	Proceeds From Collection Of Advance To Affiliate ProceedsFromCollectionOfAdvanceToAffiliate	0	USD
CY2016	us-gaap	Proceeds From Collection Of Advance To Affiliate ProceedsFromCollectionOfAdvanceToAffiliate	0	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-164978	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	164978	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	476368	USD
CY2015	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	279363	USD
CY2015	us-gaap	Depreciation Depreciation	294217	USD
CY2015	us-gaap	Adjustment For Amortization AdjustmentForAmortization	8521	USD
CY2015	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	8529005	USD
CY2015	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	106336	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6212332	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6743297	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-476368	USD
CY2015	us-gaap	Interest Paid InterestPaid	980000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5229144	USD
CY2015	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-1502870	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-2198172	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36696892	USD
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1175344	USD
CY2015	us-gaap	Proceeds From Collection Of Advance To Affiliate ProceedsFromCollectionOfAdvanceToAffiliate	1000000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5760109	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6760109	USD
CY2016	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	42886	USD
CY2015	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	59675	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	63305	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-7063100	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	56115	USD
CY2016	nnvc	Software Disposal Noncash Adjustment SoftwareDisposalNoncashAdjustment	26974	USD
CY2015	nnvc	Software Disposal Noncash Adjustment SoftwareDisposalNoncashAdjustment	0	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1000000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	0	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	6743297	USD
CY2017	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	37948	USD
CY2016	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	882386	USD
CY2015	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	877234	USD
CY2017	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	1272110	USD
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2015	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	8529005	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4864928	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2198172	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56553848	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59220515	shares
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5531708	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5028970	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-9600724	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	60955	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	62638	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10304490	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10724629	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57669472	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57669472	shares
CY2017	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1696318	USD
CY2016	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	541922	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-703766	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1865128	USD
CY2015	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	1175344	USD
CY2017	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	1347748	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	58179	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64824201	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	23048214	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36633418	USD
CY2016Q2	us-gaap	Liabilities Liabilities	13585204	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34004	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	35602	USD
CY2017Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	340695	USD
CY2016Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	767454	USD
CY2016Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	96524	USD
CY2016Q2	us-gaap	Assets Assets	36633418	USD
CY2017Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	383198	USD
CY2016Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	391467	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	75756	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	67487	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11271060	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11760767	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2505501	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1850816	USD
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13776561	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13611583	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	24381643	USD
CY2016Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	219458	USD
CY2017Q2	nnvc	Service Agreements ServiceAgreements	55414	USD
CY2017Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	190166	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	15289627	USD
CY2017Q2	us-gaap	Assets Assets	27002814	USD
CY2017Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	135786	USD
CY2017Q2	us-gaap	Liabilities Liabilities	6680872	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-75128691	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	20321942	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27002814	USD
CY2017Q2	us-gaap	Security Deposit SecurityDeposit	3515	USD
CY2016Q2	us-gaap	Security Deposit SecurityDeposit	3515	USD
CY2017Q2	us-gaap	Other Assets OtherAssets	58929	USD
CY2016Q2	us-gaap	Other Assets OtherAssets	99541	USD
CY2016Q2	nnvc	Service Agreements ServiceAgreements	96026	USD
CY2017Q2	us-gaap	Interest Payable Current InterestPayableCurrent	166667	USD
CY2016Q2	us-gaap	Interest Payable Current InterestPayableCurrent	166667	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4665518	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6744014	USD
CY2017Q2	nnvc	Deferred Interest Payable Noncurrent DeferredInterestPayableNoncurrent	0	USD
CY2016Q2	nnvc	Deferred Interest Payable Noncurrent DeferredInterestPayableNoncurrent	166667	USD
CY2017Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2015354	USD
CY2016Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6841190	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	95382979	USD
CY2016Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	87810145	USD
CY2017	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2000-07-25
CY2017	us-gaap	Business Acquisition Date Of Acquisition Agreement1 BusinessAcquisitionDateOfAcquisitionAgreement1	2005-05-12
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6616700	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6673860	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2666667	shares
CY2017	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.17
CY2016	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.19
CY2015	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.09
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10304490	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10724629	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5276036	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10304490	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10724629	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2198172	USD
CY2017	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2016	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2015	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-3077864	USD
CY2017	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.17
CY2016	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.19
CY2015	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.04
CY2016Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	9000000	USD
CY2017Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	5000000	USD
CY2016Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7996402	USD
CY2017Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7996402	USD
CY2016Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	46897	USD
CY2017Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	48486	USD
CY2016Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607	USD
CY2017Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607	USD
CY2016Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5302677	USD
CY2017Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5466066	USD
CY2017Q2	us-gaap	Land Land	260000	USD
CY2016Q2	us-gaap	Land Land	260000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	391467	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	383198	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	8270	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	8270	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8270	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	8270	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	341848	USD
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3071986	shares
CY2014Q3	nnvc	Warrants Issued To Purchase Of Common Stock WarrantsIssuedToPurchaseOfCommonStock	1926656	shares
CY2014Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.50
CY2014Q3	nnvc	Aggregate Purchase Price Of Warrants AggregatePurchasePriceOfWarrants	6743297	USD
CY2015	nnvc	Number Of Common Stock To Be Issued Upon Conversion Of Warrants NumberOfCommonStockToBeIssuedUponConversionOfWarrants	68592	shares
CY2015Q2	nnvc	Fair Value Of Common Stock Warrant Issued During Period For Consulting Services FairValueOfCommonStockWarrantIssuedDuringPeriodForConsultingServices	59675	USD
CY2016Q1	nnvc	Adjustments To Additional Paid In Capital Warrant Issued For Debenture Interest AdjustmentsToAdditionalPaidInCapitalWarrantIssuedForDebentureInterest	56115	USD
CY2013Q3	nnvc	Warrants Issued WarrantsIssued	2945428	shares
CY2014Q1	nnvc	Warrants Issued WarrantsIssued	2479935	shares
CY2013Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2810071	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2479935	shares
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	75000	shares
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.3700	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0610	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0618	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.4628	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.71	pure
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2016Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20782598	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5105024	USD
CY2016Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	8349142	USD
CY2016Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	34326764	USD
CY2016Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	34326764	USD
CY2016Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40393660	USD
CY2017Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40393660	USD
CY2017Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23839852	USD
CY2017Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6217612	USD
CY2017Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	10336196	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6066896	USD
CY2017Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	59000000	USD
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Entity Registrant Name EntityRegistrantName	NANOVIRICIDES, INC.
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0001379006
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2016Q4	dei	Entity Public Float EntityPublicFloat	44591000	USD
CY2017	dei	Trading Symbol TradingSymbol	NNVC
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	63307000	shares
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017	dei	Entity Incorporation State Country Name EntityIncorporationStateCountryName	Colorado
CY2017	us-gaap	Business Acquisition Name Of Acquired Entity BusinessAcquisitionNameOfAcquiredEntity	Edot-com.com, Inc
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58179699	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58179699	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63306774	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63306774	shares
CY2017	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	0	USD
CY2016	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	313	USD
CY2015	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	0	USD
CY2017	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0	USD
CY2016	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	332476	USD
CY2015	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0	USD
CY2017	nnvc	Bifurccation Of Embedded Derivative BifurccationOfEmbeddedDerivative	0	USD
CY2016	nnvc	Bifurccation Of Embedded Derivative BifurccationOfEmbeddedDerivative	0	USD
CY2015	nnvc	Bifurccation Of Embedded Derivative BifurccationOfEmbeddedDerivative	1879428	USD
CY2017	nnvc	Issuance Of Series C Debenture For Deposit Received IssuanceOfSeriesCDebentureForDepositReceived	0	USD
CY2016	nnvc	Issuance Of Series C Debenture For Deposit Received IssuanceOfSeriesCDebentureForDepositReceived	0	USD
CY2015	nnvc	Issuance Of Series C Debenture For Deposit Received IssuanceOfSeriesCDebentureForDepositReceived	5000000	USD
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i><u>Use of Estimates</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheet and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, accounting for share-based compensation, accounting for derivatives and accounting for income taxes. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	23369303	USD
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><u>Concentrations of Risk</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Financial instruments that potentially subject us to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured institutions in excess of federally insured limits. The Company does not believe it is exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015	nnvc	Series Preferred Shares Issued For Debenture Interest SeriesPreferredSharesIssuedForDebentureInterest	1152297	USD
CY2015	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	852760	USD
CY2016	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	882386	USD
CY2017	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	1272110	USD
CY2017	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	201313	USD
CY2016	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	158000	USD
CY2015	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	109360	USD
CY2015	nnvc	Common Stock Issued During Period Employee Stock Compensation Value Issued CommonStockIssuedDuringPeriodEmployeeStockCompensationValueIssued	125003	USD
CY2016	nnvc	Common Stock Issued During Period Employee Stock Compensation Value Issued CommonStockIssuedDuringPeriodEmployeeStockCompensationValueIssued	142589	USD
CY2017	nnvc	Common Stock Issued During Period Employee Stock Compensation Value Issued CommonStockIssuedDuringPeriodEmployeeStockCompensationValueIssued	82145	USD
CY2015	nnvc	Common Shares Issued In Connection With Warrant Conversion CommonSharesIssuedInConnectionWithWarrantConversion	6743297	USD
CY2015	nnvc	Common Stock Shares Issued For Payment Of Debenture Interest Value CommonStockSharesIssuedForPaymentOfDebentureInterestValue	1502870	USD
CY2015	nnvc	Series Preferred Shares Value Issued For Consulting And Legal Services Rendered SeriesPreferredSharesValueIssuedForConsultingAndLegalServicesRendered	24474	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	31785867	USD
CY2017	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	45000	USD
CY2016	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	45000	USD
CY2017	nnvc	Common Stock Shares Issued For Payment Of Debenture Interest Value CommonStockSharesIssuedForPaymentOfDebentureInterestValue	607178	USD
CY2016	nnvc	Common Stock Shares Issued For Payment Of Debenture Interest Value CommonStockSharesIssuedForPaymentOfDebentureInterestValue	660000	USD
CY2015	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	45000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2017	us-gaap	Debt Instrument Redemption Description DebtInstrumentRedemptionDescription	the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the common stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of common stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the common stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of common Stock (the Redemption Warrants, and collectively with (i) (iv), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8270	USD
CY2014Q4	nnvc	Acquisition And Renovation Expenses Of Manufacturing And Lab Facility AcquisitionAndRenovationExpensesOfManufacturingAndLabFacility	4222549	USD
CY2014Q4	nnvc	Closing Costs Of Facility ClosingCostsOfFacility	81230	USD
CY2016	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	332476	USD
CY2017	us-gaap	Interest Expense InterestExpense	780767	USD
CY2016	us-gaap	Interest Expense InterestExpense	1042470	USD
CY2015	us-gaap	Interest Expense InterestExpense	2649592	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-332524	USD
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2016	nnvc	Adjustments To Additional Paid In Capital Warrant Issued For Debenture Interest AdjustmentsToAdditionalPaidInCapitalWarrantIssuedForDebentureInterest	56115	USD
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5332524	USD
CY2017	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1000000	USD
CY2016	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2015	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2017	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	charge its costs (direct and indirect) plus no more than 30% of direct costs
CY2017	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2000	USD
CY2016	nnvc	Net Proceeds From Issuance Of Debt NetProceedsFromIssuanceOfDebt	1968275	USD
CY2017	nnvc	Net Proceeds From Issuance Of Debt NetProceedsFromIssuanceOfDebt	1968275	USD
CY2017	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	5000000	USD
CY2017Q1	us-gaap	Interest Payable Current InterestPayableCurrent	27178	USD
CY2017Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	24266	USD
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1.23
CY2017Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1000000	USD
CY2017Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	332524	USD
CY2017Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	5332524	USD
CY2015	us-gaap	Stock Issued During Period Shares Share Based Compensation Gross StockIssuedDuringPeriodSharesShareBasedCompensationGross	200508	shares
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	852760	USD
CY2016	us-gaap	Stock Issued During Period Shares Share Based Compensation Gross StockIssuedDuringPeriodSharesShareBasedCompensationGross	507649	shares
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2011207	USD
CY2015	us-gaap	Fair Value Measurements Significant Assumptions FairValueMeasurementsSignificantAssumptions	a. The common stock price was in the range $2.29 to $1.55; b. The calculated weighted average number of shares of common stock in the period; c. A 5.36% premium over the common shares for the voting preferences; d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 4.896% to 5.046% of the total; e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from March 1, 2013 and a remaining restricted term of 1.92 to 1.67 years; f. 30.86% to 31.42% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 63.52% to 69.38% volatility, 0. 22% to 0.26% risk free rate) applied to the converted common.
CY2016	us-gaap	Fair Value Measurements Significant Assumptions FairValueMeasurementsSignificantAssumptions	a. The common stock price was in the range $1.82 to $1.20; b. The calculated weighted average number of shares of common stock in the period; c. A 5.36% premium over the common shares for the voting preferences; d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 4.896% to 5.046% of the total; e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from March 1, 2013 and a remaining restricted term of 1.92 to 1.67 years; f. 30.86% to 31.42% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 63.52% to 69.38% volatility, 0.22% to 0.26% risk free rate) applied to the converted common.
CY2017	nnvc	Preferred Stock Issued As Discount On Debenture PreferredStockIssuedAsDiscountOnDebenture	0	USD
CY2016	nnvc	Preferred Stock Issued As Discount On Debenture PreferredStockIssuedAsDiscountOnDebenture	0	USD
CY2015	nnvc	Preferred Stock Issued As Discount On Debenture PreferredStockIssuedAsDiscountOnDebenture	1152297	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	313155	shares
CY2015	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	59675	USD
CY2016	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	42886	USD
CY2017	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	37948	USD
CY2017	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	0	USD
CY2016	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-3515	USD
CY2015	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	150000	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-40612	USD
CY2016	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-46505	USD
CY2015	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	142531	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	39262	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	7007	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-286930	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-426759	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	451258	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	266741	USD
CY2017	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1598	USD
CY2016	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	7087	USD
CY2015	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-63323	USD
CY2017	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-166667	USD
CY2016	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-166666	USD
CY2015	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	500000	USD
CY2017	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Note 1 Organization and Nature of Business</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">NanoViricides, Inc. (the “Company”) was incorporated under the laws of the State of Colorado on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> July 25, 2000</font> as Edot-com.com, Inc<b>.</b> which was organized for the purpose of conducting internet retail sales.  On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation.  On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 12, 2005</font>, the corporations were merged and Edot-com.com, Inc<b>.,</b> the Nevada corporation, became the surviving entity.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired Nanoviricide, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”).  Nanoviricide, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80,000,000</font> newly issued shares of ECMM common stock resulting in an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font> million shares of ECMM common stock issued and outstanding.  NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000</font> shares of the Company’s common stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As a result of the Exchange transaction, the former NVI stockholders held approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of ECCM by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.  Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. NanoViricides is unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and e-GMP-like production in quantities needed for human clinical trials. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations.</font></div>    <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On February 15, 2010 the Company executed an Additional License Agreement with TheraCour.  Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a one-time licensing fee equal to 2,000,000 shares (adjusted for the 3.5 to 1 reverse split) of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).  The Series A Preferred Stock is convertible, only in the event of a “change of control” of the Company, as defined in the designation of Series A Preferred Stock (see Note 2 for further details), into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Series A Preferred Stock do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the Holder’s approval. The <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares were valued at the par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000</font>.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	nnvc	Common Stock Issued During Period Settlement Of Accounts Payable Shares CommonStockIssuedDuringPeriodSettlementOfAccountsPayableShares	71430	shares
CY2017	nnvc	Common Stock Issued During Period Settlement Of Accounts Payable Value CommonStockIssuedDuringPeriodSettlementOfAccountsPayableValue	82145	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2017	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	the converted value to common at a ratio of 1:3.5
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	5000000	USD
CY2017Q1	nnvc	Conversion Price Of Shares Converted ConversionPriceOfSharesConverted	1.1533
CY2016	nnvc	Restricted Common Stock Authorized For Interest Payable RestrictedCommonStockAuthorizedForInterestPayable	313785	shares
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	158000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0687	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0495	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.4582	pure
CY2017	us-gaap	Fair Value Measurements Significant Assumptions FairValueMeasurementsSignificantAssumptions	a. The common stock price was in the range $1.07 to $1.74; b. The calculated weighted average number of shares of common stock in the period; c. A 26.63% premium over the common shares for the voting preferences; d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 10.25% to 12.26% of the total; e. The conversion value was based on an assumption for calculation purposes only, for the period ended September 30, 2016 of a Change of Control in 4 years from March 1, 2013 and a remaining restricted term of 1.92 to 1.67 years. For the period from October 1, 2016 to June 30, 2017, the conversion value was based on an assumption for calculation purposes only of a Change of Control in 4 years and a remaining restricted term of 4 to 3.34 years; f. 21.76% to 38.87% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 63.58% to 85.39% volatility, 0.37% to 1.50% risk free rate) applied to the converted common.
CY2017	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Reclassifications</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results or operations.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name	View Source	Status
0001144204-17-050412-index-headers.html	Edgar Link	pending
0001144204-17-050412-index.html	Edgar Link	pending
0001144204-17-050412.txt	Edgar Link	pending
0001144204-17-050412-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nnvc-20170630.xml	Edgar Link	completed
nnvc-20170630.xsd	Edgar Link	pending
nnvc-20170630_cal.xml	Edgar Link	unprocessable
nnvc-20170630_def.xml	Edgar Link	unprocessable
nnvc-20170630_lab.xml	Edgar Link	unprocessable
nnvc-20170630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v474679_10k.htm	Edgar Link	pending
v474679_ex31-1.htm	Edgar Link	pending
v474679_ex31-2.htm	Edgar Link	pending
v474679_ex32-1.htm	Edgar Link	pending
v474679_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NNVC
NANOVIRICIDES, INC. Stock $nnvc

2017 Q2 Form 10-K Financial Statement

#000114420417050412 Filed on September 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC NANOVIRICIDES, INC. Stock $nnvc

2017 Q2 Form 10-K Financial Statement

#000114420417050412 Filed on September 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC
NANOVIRICIDES, INC. Stock $nnvc